PD-L1 (CPS) >= 10
About
Biomarker Type: Protein expression
Present: True
Marker: PD-L1
Unit: Combined Positive Score (CPS)
Equality: >=
Value: 10
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | PD-L1 (CPS) >= 10 | Adenocarcinoma of the Gastroesophageal Junction | Pembrolizumab | |
| FDA (1) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Pembrolizumab | |
| EMA (1) FDA (1) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Paclitaxel, Pembrolizumab | |
| EMA (1) FDA (1) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Carboplatin, Gemcitabine, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 10 | Bladder Urothelial Carcinoma | Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Cisplatin, Fluorouracil, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Carboplatin, Fluorouracil, Pembrolizumab | |
| EMA (1) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Nab-paclitaxel, Pembrolizumab |